OPKO Health: Barrington upgrade meets bearish options bet ahead of earnings

Barrington Research reversed its April downgrade on OPK on 16 October, lifting the stock back to Outperform. Piper Sandler moved on the same day, raising its price target from $3.00 to $4.00 while reiterating Overweight. The consensus sits at buy, with a mean target of $4.15 against a close of $1.53, implying substantial distance between where analysts think the stock should trade and where it does.

Analysts pivot, options market pushes back

The two analyst actions landed as the stock was up 10.9% on the week to $1.61. But the options market read the setup differently. The put-call ratio on 16 October hit 0.0523, 3.4 standard deviations above its 20-day mean of 0.0427. That is close to the 52-week high of 0.069. Earnings are due on 28 October, nine days away, and the options positioning signals that not everyone is persuaded by the analyst turn.

The contrast is sharp. Barrington's Michael Petusky downgraded OPK to Market Perform in April after cutting his target in March, then reversed course within six months. That kind of round-trip matters as context. The bear case rests on a difficult fundamental setup: Q1 revenue of $124.2m and EPS of -$0.07 both missed, and the company needs a sharp second-half acceleration to hit its own guidance of $530m to $560m for the full year.

Short sellers and the borrow market

Short interest stands at 5.0% of free float, up 9.5% over the past week to around 38.4 million shares. That is a meaningful move. Cost to borrow spiked to 0.94% mid-week before settling back to 0.60%, still up around 16.5% on the week. Availability in the lending pool sits at 335%, well above the 52-week trough of 286%, so the borrow market is not particularly stressed despite the short interest build. There is no acute squeeze pressure from the lending side.

The 30-day EPS momentum factor ranks at the 97th percentile, a high reading. The analyst recommendation factor scores at the 94th percentile, reflecting the recent upgrade cluster. Neither signals fundamental improvement on its own, but together they explain why the stock moved on the analyst action.

What to watch

Earnings on 28 October are the pin. The prior Q2 print sent the stock up 35% in a single session. The options market, building put exposure at a 3.4 standard deviation extreme relative to recent history, is pricing for a different outcome this time. The gap between the $4.15 consensus target and the $1.53 close will either narrow quickly or the analyst upgrades will look premature.

---

Data summary

• SI % of free float: 5.0%, up 9.5% in one week
• Cost to borrow: 0.60% (16 Oct), peak 0.94% on 15 Oct, up ~16.5% on the week
• Availability: 335%, down 16.2% week-on-week, 52-week range 286% to 472%
• Put-call ratio: 0.0523, z-score +3.4 vs 20-day mean of 0.0427
• Analyst consensus: buy; mean target $4.15; Piper Sandler target raised to $4.00; Barrington upgraded to Outperform
• Next earnings: 28 October 2026